Interferons in relapsing remitting multiple sclerosis.

Interferons in relapsing remitting multiple sclerosis.

Λεπτομέρειες βιβλιογραφικής εγγραφής
Κύριος συγγραφέας:	Goodin, D
Μορφή:	Journal article
Γλώσσα:	English
Έκδοση:	2003

Παρόμοια τεκμήρια

Interferons in relapsing remitting multiple sclerosis - Authors' reply
ανά: Filippini, G, κ.ά.
Έκδοση: (2003)

Interferons in relapsing remitting multiple sclerosis - Authors' reply
ανά: Filippini, G, κ.ά.
Έκδοση: (2003)

Interferons in relapsing remitting multiple sclerosis: a systematic review.
ανά: Filippini, G, κ.ά.
Έκδοση: (2003)

Interferon-beta for relapsing-remitting multiple sclerosis: a systematic review
ανά: Dian HE, κ.ά.
Έκδοση: (2014-09-01)

Profile of PEGylated interferon beta in the treatment of relapsing-remitting multiple sclerosis
ανά: Cocco E, κ.ά.
Έκδοση: (2015-05-01)

Erratum to Interferon-beta for relapsing-remitting multiple sclerosis: a systematic review
ανά: Dian HE
Έκδοση: (2015-01-01)

Approved Beta Interferons in Relapsing-Remitting Multiple Sclerosis: Is there an odd one Out?
ανά: Alexis Clapin
Έκδοση: (2012-04-01)

Approved Beta Interferons in Relapsing-Remitting Multiple Sclerosis: is there a one odd out?
ανά: Alexis Clapin
Έκδοση: (2012-09-01)

Response to treatment with Interferon beta-1a in patients with relapsing-remitting multiple sclerosis
ανά: Làzaro Aurelio Vàzquez Gòmez, κ.ά.
Έκδοση: (2022-10-01)

Thalamic neurodegeneration in relapsing-remitting multiple sclerosis.
ανά: Wylezinska, M, κ.ά.
Έκδοση: (2003)

Thalamic neurodegeneration in relapsing: Remitting multiple sclerosis
ανά: Cifelli, A, κ.ά.
Έκδοση: (2003)

Comorbidity in in patients with relapsing-remitting multiple sclerosis
ανά: O.V. Somilo, κ.ά.
Έκδοση: (2024-10-01)

Fingolimod for the Treatment of Relapsing-Remitting Multiple Sclerosis
ανά: Burcu Altunrende, κ.ά.
Έκδοση: (2017-12-01)

Advances in the treatment of relapsing - Remitting multiple sclerosis
ανά: Radu Tanasescu, κ.ά.
Έκδοση: (2014-04-01)

Postural Control in Relapsing-Remitting Multiple Sclerosis
ανά: Flavia Salvaterra Cusin, κ.ά.
Έκδοση: (2022-10-01)

Cognitive impairment in relapsing remitting Multiple Sclerosis
ανά: Saška Roškar
Έκδοση: (2003-06-01)

Multiple Sclerosis Relapsing Remitting Progressive Type
ανά: Nora Fitri, κ.ά.
Έκδοση: (2020-12-01)

Direct costs of relapses in patients with relapsing-remitting multiple sclerosis
ανά: V. Casado, κ.ά.
Έκδοση: (2021-07-01)

Longitudinal analyses of the effects of neutralizing antibodies on interferon beta-1b in relapsing-remitting multiple sclerosis.
ανά: Petkau, A, κ.ά.
Έκδοση: (2004)

Longitudinal analyses of the effects of neutralizing antibodies on interferon beta-1b in relapsing-remitting multiple sclerosis
ανά: Petkau, A, κ.ά.
Έκδοση: (2004)

Cost-utility analysis of interferon beta-1a (Avonex and Cinnovex) for relapsing remitting multiple sclerosis
ανά: Rahil Sadat Shahtaheri, κ.ά.
Έκδοση: (2018-06-01)

Experience with the long-term use of interferons β in the treatment of relapsing-remitting multiple sclerosis. Case report
ανά: Taras O. Simaniv, κ.ά.
Έκδοση: (2024-12-01)

Biomarkers of response to ocrelizumab in relapsing–remitting multiple sclerosis
ανά: Fernando Rodríguez-Jorge, κ.ά.
Έκδοση: (2024-11-01)

Oxidative stress in relapsing-remitting multiple sclerosis patients
ανά: Samaneh Sabouri, κ.ά.
Έκδοση: (2023-09-01)

Effectiveness of Copaxone in patients with relapsing-remitting multiple sclerosis
ανά: V. M. Alifirova, κ.ά.
Έκδοση: (2010-08-01)

Subcutaneous Ofatumumab in Patients with Relapsing-remitting Multiple Sclerosis
ανά: Halil Önder
Έκδοση: (2019-06-01)

Serum prolactin in patients with relapsing remitting multiple sclerosis
ανά: Hoda A. Alwakil, κ.ά.
Έκδοση: (2020-07-01)

Prolyl oligopeptidase is inhibited in relapsing-remitting multiple sclerosis
ανά: Burgal María, κ.ά.
Έκδοση: (2010-04-01)

Mild cognitive impairment in relapsing-remitting multiple sclerosis
ανά: Dimakopoulou Aikaterini, κ.ά.
Έκδοση: (2008-04-01)

Cognitive profile of patients with relapsing remitting multiple sclerosis
ανά: VIVIAN M. ANDRADE, κ.ά.
Έκδοση: (1999-09-01)

The Cost of Relapsing-Remitting Multiple Sclerosis Patients Who Develop Neutralizing Antibodies during Interferon Beta Therapy.
ανά: Damiano Paolicelli, κ.ά.
Έκδοση: (2016-01-01)

Profiling of Canonical and Non-Traditional Cytokine Levels in Interferon-β-Treated Relapsing–Remitting-Multiple Sclerosis Patients
ανά: Chiara D’Angelo, κ.ά.
Έκδοση: (2018-06-01)

Cerebellar information processing in relapsing-remitting multiple sclerosis (RRMS).
ανά: Lesage, E, κ.ά.
Έκδοση: (2010)

Cerebellar Information Processing in Relapsing-Remitting Multiple Sclerosis (RRMS)
ανά: E. Lesage, κ.ά.
Έκδοση: (2010-01-01)

Risk-benefit considerations in the treatment of relapsing-remitting multiple sclerosis
ανά: Lugaresi A, κ.ά.
Έκδοση: (2013-06-01)

Management of relapsing-remitting multiple sclerosis: diagnosis and treatment guidelines
ανά: Paty, D, κ.ά.
Έκδοση: (1999)

Subtypes of relapsing-remitting multiple sclerosis identified by network analysis
ανά: Quentin Howlett-Prieto, κ.ά.
Έκδοση: (2023-01-01)

Cytotoxic B Cells in Relapsing-Remitting Multiple Sclerosis Patients
ανά: Vinícius O. Boldrini, κ.ά.
Έκδοση: (2022-02-01)

Altered Serum Cytokine Profiles in Relapse Phase of Relapsing-Remitting Multiple Sclerosis
ανά: Forooz Peiravian, κ.ά.
Έκδοση: (2016-09-01)

Corrigendum: Biomarkers of response to ocrelizumab in relapsing–remitting multiple sclerosis
ανά: Fernando Rodríguez-Jorge, κ.ά.
Έκδοση: (2024-12-01)